US20040081631A1 - Cosmetic composition for skin whitening comprising senkyunolide a as active ingredient - Google Patents
Cosmetic composition for skin whitening comprising senkyunolide a as active ingredient Download PDFInfo
- Publication number
- US20040081631A1 US20040081631A1 US10/353,010 US35301003A US2004081631A1 US 20040081631 A1 US20040081631 A1 US 20040081631A1 US 35301003 A US35301003 A US 35301003A US 2004081631 A1 US2004081631 A1 US 2004081631A1
- Authority
- US
- United States
- Prior art keywords
- senkyunolide
- skin
- msh
- present
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- ZPIKVDODKLJKIN-NSHDSACASA-N Senkyunolide Chemical compound C1CC=CC2=C1[C@H](CCCC)OC2=O ZPIKVDODKLJKIN-NSHDSACASA-N 0.000 title claims abstract description 124
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 239000002537 cosmetic Substances 0.000 title claims abstract description 21
- 239000004480 active ingredient Substances 0.000 title claims abstract description 8
- 230000002087 whitening effect Effects 0.000 title claims description 7
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 claims abstract description 25
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 claims abstract description 25
- 241000244365 Ligusticum sinense Species 0.000 claims abstract description 16
- 241000533367 Cnidium officinale Species 0.000 claims abstract description 15
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 12
- 239000006071 cream Substances 0.000 claims description 16
- 239000006210 lotion Substances 0.000 claims description 13
- 239000000839 emulsion Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 239000007921 spray Substances 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 16
- 230000005764 inhibitory process Effects 0.000 abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 30
- 238000009472 formulation Methods 0.000 description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 14
- 239000004615 ingredient Substances 0.000 description 13
- 210000002752 melanocyte Anatomy 0.000 description 13
- 230000008099 melanin synthesis Effects 0.000 description 12
- 102000003425 Tyrosinase Human genes 0.000 description 10
- 108060008724 Tyrosinase Proteins 0.000 description 10
- 235000015097 nutrients Nutrition 0.000 description 10
- 239000003086 colorant Substances 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 8
- -1 albutin Chemical compound 0.000 description 7
- 230000002421 anti-septic effect Effects 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229920002385 Sodium hyaluronate Polymers 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 235000019439 ethyl acetate Nutrition 0.000 description 5
- 229940093499 ethyl acetate Drugs 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 5
- 229940010747 sodium hyaluronate Drugs 0.000 description 5
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- WNZQDUSMALZDQF-UHFFFAOYSA-N 2-benzofuran-1(3H)-one Chemical compound C1=CC=C2C(=O)OCC2=C1 WNZQDUSMALZDQF-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 230000001815 facial effect Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 229960004418 trolamine Drugs 0.000 description 4
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- YFTGOBNOJKXZJC-UHFFFAOYSA-N 5,6-dihydroxyindole-2-carboxylic acid Chemical compound OC1=C(O)C=C2NC(C(=O)O)=CC2=C1 YFTGOBNOJKXZJC-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 3
- 239000007844 bleaching agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 229940113124 polysorbate 60 Drugs 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 229950011392 sorbitan stearate Drugs 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- DQNGMIQSXNGHOA-UMEXKXKESA-N (3e,6s,7s)-3-butylidene-6,7-dihydroxy-4,5,6,7-tetrahydro-2-benzofuran-1-one Chemical compound C1([C@@H]([C@@H](O)CC2)O)=C2C(=C/CCC)\OC1=O DQNGMIQSXNGHOA-UMEXKXKESA-N 0.000 description 2
- WMBOCUXXNSOQHM-FLIBITNWSA-N (Z)-3-butylidenephthalide Chemical compound C1=CC=C2C(=C/CCC)/OC(=O)C2=C1 WMBOCUXXNSOQHM-FLIBITNWSA-N 0.000 description 2
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- SGNZYJXNUURYCH-UHFFFAOYSA-N 5,6-dihydroxyindole Chemical compound C1=C(O)C(O)=CC2=C1NC=C2 SGNZYJXNUURYCH-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 238000003988 headspace gas chromatography Methods 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003061 melanogenesis Effects 0.000 description 2
- WMBOCUXXNSOQHM-UHFFFAOYSA-N n-butylidenephthalide Natural products C1=CC=C2C(=CCCC)OC(=O)C2=C1 WMBOCUXXNSOQHM-UHFFFAOYSA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- DQNGMIQSXNGHOA-UHFFFAOYSA-N senkyunolide-H Natural products C1CC(O)C(O)C2=C1C(=CCCC)OC2=O DQNGMIQSXNGHOA-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 229940066528 trichloroacetate Drugs 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- XKAWDGBGOZLBRY-XFFZJAGNSA-N (3z)-3-(2-hydroxybutylidene)-4,5-dihydro-2-benzofuran-1-one Chemical compound C1CC=CC2=C1C(=C/C(O)CC)/OC2=O XKAWDGBGOZLBRY-XFFZJAGNSA-N 0.000 description 1
- FCZPMYNMCGYTCA-YFHOEESVSA-N (3z)-3-butylidene-4-hydroxy-2-benzofuran-1-one Chemical compound C1=CC(O)=C2C(=C/CCC)/OC(=O)C2=C1 FCZPMYNMCGYTCA-YFHOEESVSA-N 0.000 description 1
- DQNGMIQSXNGHOA-RCBCECLLSA-N (3z,6s,7r)-3-butylidene-6,7-dihydroxy-4,5,6,7-tetrahydro-2-benzofuran-1-one Chemical compound C1([C@H]([C@@H](O)CC2)O)=C2C(=C/CCC)/OC1=O DQNGMIQSXNGHOA-RCBCECLLSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- WMBOCUXXNSOQHM-DHZHZOJOSA-N 3-Butylidenephthalide Natural products C1=CC=C2C(=C/CCC)\OC(=O)C2=C1 WMBOCUXXNSOQHM-DHZHZOJOSA-N 0.000 description 1
- BOADILHGMFLLBY-UHFFFAOYSA-N 3-butyl-6,7-dihydro-3h-2-benzofuran-1-one Chemical compound C1=CCCC2=C1C(CCCC)OC2=O BOADILHGMFLLBY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- ZPIKVDODKLJKIN-UHFFFAOYSA-N CCCCC1OC(=O)C2=C1CCC=C2 Chemical compound CCCCC1OC(=O)C2=C1CCC=C2 ZPIKVDODKLJKIN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000212948 Cnidium Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000208680 Hamamelis mollis Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- UPJFTVFLSIQQAV-KOLCDFICSA-N Neocnidilide Chemical compound C1CC[C@H]2[C@H](CCCC)OC(=O)C2=C1 UPJFTVFLSIQQAV-KOLCDFICSA-N 0.000 description 1
- UPJFTVFLSIQQAV-UHFFFAOYSA-N Neocnidilide Natural products C1CCC2C(CCCC)OC(=O)C2=C1 UPJFTVFLSIQQAV-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 210000002639 dermal melanocyte Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940049294 glyceryl stearate se Drugs 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 150000004693 imidazolium salts Chemical class 0.000 description 1
- 229940060384 isostearyl isostearate Drugs 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- NEMFQSKAPLGFIP-UHFFFAOYSA-N magnesiosodium Chemical compound [Na].[Mg] NEMFQSKAPLGFIP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N phthalic anhydride Chemical class C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 125000005506 phthalide group Chemical group 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- XKAWDGBGOZLBRY-UHFFFAOYSA-N senkyunolide-F Natural products C1CC=CC2=C1C(=CC(O)CC)OC2=O XKAWDGBGOZLBRY-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000010284 shimotsu-to Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940118846 witch hazel Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0212—Face masks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Definitions
- the present invention relates to a cosmetic composition and more particularly, to a cosmetic composition for skin whitening comprising senkyunolide A as an active ingredient and its applications.
- UV-irradiated epidermal keratinocytes secrete melanin-inducing factors resulting in synthesis of melanin from activated dermal melanocytes and the secreted melanin on epidermis pigments the skin.
- tyrosinase converts tyrosine into dopaquinone and its oxidized derivative, dopachrome, is consecutively oxidized into 5,6-dihydroxyindole (DHI) and 5,6-dihydroxyindole-2-carboxylic acid (DHICA).
- DHI 5,6-dihydroxyindole
- DHICA 5,6-dihydroxyindole-2-carboxylic acid
- tyrosinase inhibitors are kojic acid, albutin, hydroquinone, vitamin C and extracts of various natural materials.
- the present inventors have been endeavored to alleviate the melanin-inducing stimuli such as UV irradiation and to inhibit the UV-derived physiological activity and synthesis of melanin-inducing factors.
- the present inventors gave a due investigation on candidate substances enabling to inhibit melanin synthesis induced by melanocyte-stimulating hormone (MSH).
- MSH melanocyte-stimulating hormone
- ⁇ -melanocyte stimulating hormone (CL MSH) expressed by UV irradiation or pregnancy binds to its receptor on melanocyte leading to increase of melanin via activation of melanocyte, tyrosinase and melanocyte dendrite. Consequently, it is highly probable to gain skin-whitening effect and alleviation of pigmentation by inhibiting a MSH. For that reason, the need of inhibitors for a MSH has been highly rising in the art.
- MSH melanocyte stimulating hormone
- a cosmetic composition for skin whitening comprising: (a) a senkyunolide A as an active ingredient; and (b) a cosmetically acceptable carrier.
- composition for inhibiting melanocyte-stimulating hormone comprising senkyunolide A as an active ingredient.
- Senkyunolide A (3-butyl-6,7-dihydrophthalide), a naturally occurring phthalide, is represented by the following formula I:
- the senkyunolide A used has been isolated from Cnidium officinale or Ligusticum chuanxiong , which are perennial herbs of Umbelliferae.
- Cnidium officinale comprises ligustilide, butylidenephthalide, sekyunolide A and sekyunonlide H (Kobayashi S. et al., Antiproliferative effects of the traditional Chinese medicine shimotsu-to, its component Cnidium rhizome and derived compounds on primary cultures of mouse aorta smooth muscle cells. Jpn J Pharmacol. 1992.
- Ligusticum chuanxiong comprises 3-butylphthaldie, 3-butylidenephthalide, 3-butylidene-4-hydroxyphthalide, neocnidilide, Z-ligustilide, E-ligustilide, senkyunolide A, senkyunolide F, senkyunolide H and senkyunolide I (Li H X. et al., Separation and identification of the phthalic anhydride derivatives of Liqusticum chuanxiong Hort by GC-MS, TLC, HPLC-DAD and HPLC-MS. 2002. J Chromatogr Sci. 40(3): 156-61).
- the senkyunolide A of the invention showed a novel MSH-inhibitory activity and more enhanced skin-whitening effect than conventional whitening agents showing inhibition of tyrosinase activity.
- the purified senkyunolide A according to the present invention is a potential candidate for skin-whitening agent since its IC 50 is much lower than extract of Cnidium officinale or Ligusticum chuanxiong.
- senkyunolide A of the present invention is isolated from the extract of Cnidium officinale or Ligusticum chuanxiong .
- the extract of Cnidium officinale or Ligusticum chuanxiong may be acquired using various extraction solvents, e.g. (a) water, (b) anhydrous or hydrous lower alcohol containing 1-4 carbon atoms (methanol, ethanol, propanol, butanol, etc.), (c) mixture of the lower alcohol and water, (d) acetone, (e) ethyl acetate, (f) chloroform, (g) 1,3-butyleneglycol, (h) butyl acetate.
- More preferable extraction solvent for this invention is the hydrous lower alcohol, and the most preferable solvent is ethanol.
- other conventional solvents may be employed for substantially similar isolating efficiency.
- Senkyunolide A according to the present invention can be isolated and purified from Cnidium officinale or Ligusticum chuanxiong using the known methods in the art.
- the isolation and purification may employ gas chromatography (GC), head space gas chromatography (HSGC), liquid chromatography (LC), high performance liquid chromatography (HPLC) and thin layer chromatography (TLC).
- GC gas chromatography
- HSGC head space gas chromatography
- LC liquid chromatography
- HPLC high performance liquid chromatography
- TLC thin layer chromatography
- the present invention may employ senkyunolide A prepared by not only isolating from Cnidium officinale or Ligusticum chuanxiong extract but also synthesizing chemically.
- the effective amount of senkyunolide A in cosmetic composition is 0.00001-20 wt %, and more preferably 0.00001-10 wt % based on the total weight of the cosmetic composition.
- the amount of senkyunolide A is lower than 0.00001 wt %, the aimed skin-whitening effect may be negligible; in the case of exceeding 20 wt %, some adverse effects such as skin irritation and instability in formulation is very likely to occur.
- the cosmetic compositions of the present invention may contain auxiliaries as well as carrier in addition to senkyunolide A.
- auxiliaries include preservatives, antioxidants, stabilizers, solubilizers, vitamins, colorants, odor improvers or mixtures of these ingredients.
- the cosmetic compositions of this invention may be formulated in a wide variety of form, for non-limited example, including a solution, a suspension, an emulsion, a paste, an ointment, a gel, a cream, a lotion, a powder, a soap, a surfactant-containing cleanser, an oil, a powder foundation, an emulsion foundation, a wax foundation and a spray.
- the cosmetic composition of the present invention can be provided in a form of skin softener (skin lotion), astringent lotion, nutrient emulsion (milk lotion), nutrient cream, message cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, facial pack, spray or powder.
- the cosmetically acceptable carrier contained in the present cosmetic composition may be varied depending on the type of the formulation.
- the formulation of ointment, pastes, creams or gels may comprise animal and vegetable fats, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silica, talc, zinc oxide or mixtures of these ingredients.
- powder or spray it may comprise lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder and mixtures of these ingredients.
- Spray may additionally comprise the customary propellants, for example, chlorofluorohydrocarbons, propane/butane or dimethyl ether.
- the formulation of solution and emulsion may comprise solvent, solubilizer and emulsifier, for example water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyleneglycol, oils, in particular cottonseed oil, groundnut oil, maize germ oil, olive oil, castor oil and sesame seed oil, glycerol fatty esters, polyethylene glycol and fatty acid esters of sorbitan or mixtures of these ingredients.
- solvent solubilizer and emulsifier
- solubilizer and emulsifier for example water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyleneglycol, oils, in particular cottonseed oil, groundnut oil, maize germ oil, olive oil
- the formulation of suspension may comprise liquid diluents, for example water, ethanol or propylene glycol, suspending agents, for example ethoxylated isosteary alcohols, polyoxyethylene sorbitol esters and poly oxyethylene sorbitan esters, micocrystalline cellulose, aluminum metahydroxide, bentonite, agar and tragacanth or mixtures of these ingredients.
- liquid diluents for example water, ethanol or propylene glycol
- suspending agents for example ethoxylated isosteary alcohols, polyoxyethylene sorbitol esters and poly oxyethylene sorbitan esters, micocrystalline cellulose, aluminum metahydroxide, bentonite, agar and tragacanth or mixtures of these ingredients.
- the formulation of cleansing compositions with surfactant may comprise aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosucinnate monoester, isothinate, imidazolium derivatives, methyltaurate, sarcocinate, fatty acid amide ether sulfate, alkyl amido betain, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanoline derivatives, ethoxylated glycerol fatty acid ester or mixtures of these ingredients.
- R f 0.5 was pre-determined via prep-TLC with the control of senkyunolide A commercially available.
- senkyunolide A 3.1 g was finally purified through prep-LC, distillation under vacuum and removal of residual solvent using vacuum pump, consecutively:
- Melanocytes (mouse B-16 melanoma strain; ATCC CRL 6323) were purchased from ATCC (USA). The melanocytes were maintained in T-flask supplemented with DMEM containing 4.5 g/L glucose, 10% FBS (fetal bovine serum) and 1% penicillin-streptomycin in a humidified incubator supplied with 5% CO 2 at 3° C. After 24 h incubation, cells were detached by trypsinization and 5 ⁇ 10 4 cells were plated on each 100 mm plate supplemented with fresh medium.
- DMEM fetal bovine serum
- senkyunolide A according to the present invention was found to decrease melanin synthesis of melanocytes induced by MSH in a dose dependent manner and 50 ⁇ g/ml of senkyunolide A inhibited the melanin synthesis to the level below the amount of MSH-uninduced melanocytes (100%).
- senkyunolide A of the present invention was found to decrease the tyrosinase expression in melanocytes in a dose dependent manner and 50 ⁇ g/ml senkyunolide A caused the similar band intensity to tyrosinase of MSH-uninduced melanocytes.
- the formulations of the present invention can be provided in a form of skin softener (skin lotion), astringent lotion, nutrient emulsion (milk lotion), nutrient cream, message cream, essence, facial pack without limiting the applicable formulations therein.
- Formulation I Skin Lotion (Skin Softener)
- One example of skin lotion containing senkyunolide A according to the present invention is formulated as below: TABLE III Ingredients Amount (wt %) Senkyunolide A 1.0 Glycerine 5.0 1,3-butylglycol 3.0 PEG 150 1.0 Alantoine 0.1 DL-pantenol 0.3 EDTA-2Na 0.02 Benzophenon-9 0.04 Sodium hyaluronate 5.0 Ethanol 10.0 Octyldodeces-16 0.2 Polysorbate 20 0.2 Antiseptic, fragrant, colorant Small amount DW To be total Total 100
- astringent lotion containing senkyunolide A of the present invention is formulated as below Table IV: TABLE IV Ingredients Amount (wt %) Senkyunolide A 1.0 Glycerine 2.0 1,3-butylglycol 2.0 Alantoine 0.2 DL-pantenol 0.2 EDTA-2Na 0.02 Benzophenon-9 0.04 Sodium hyaluronate 3.0 Ethanol 15.0 Polysorbate 20 0.3 Witchhazel extract 2.0 Citric acid Small amount Antiseptic, fragrant, colorant Small amount DW To be total Total 100
- senkyunolide A of the present invention is formulated as below Table V: TABLE V Ingredients Amount (wt %) Senkyunolide A 1.5 Glyceryl stearate SE 1.5 Stearyl alcohol 1.5 Lanoline 1.5 Polysorbate 60 1.3 Sorbitan stearate 0.5 Hydrogenated vegetable oil 1.0 Mineral oil 5.0 Squalane 3.0 Trioctanoine 2.0 Dimethicon 0.8 Tocopherol acetate 0.5 Carboxyvinyl polymer 0.12 Glycerine 5.0 1,3-butylglycol 3.0 Sodium hyaluronate 5.0 Tri-ethanolamine 0.12 Antiseptic, fragrant, colorant Small amount DW To be total Total 100
- nutrient cream containing senkyunolide A of the present invention is formulated as below Table VI: TABLE VI Ingredients Amount (wt %) Senkyunolide A 5.0 Lypophilic glycerol monostearate 2.0 Cetearyl alcohol 2.2 Stearic acid 1.5 Wax 1.0 Polysorbate 60 1.5 Sorbitan stearate 0.6 Hydrogenated vegetable oil 1.0 Squalane 3.0 Mineral oil 5.0 Trioctanoine 5.0 Dimethicon 1.0 Sodium magnesium silicate 0.1 Glycerine 5.0 Betaine 3.0 Tri-ethanolamine 1.0 Sodium hyaluronate 4.0 Antiseptic, fragrant, colorant Small amount DW To be total Total 100
- TABEL VII Ingredients Amount (wt %) Senkyunolide A 1.0 Lypophilic glycerol monostearate 1.5 Stearyl alcohol 1.5 Stearic acid 1.0 Polysorbate 60 1.5 Sorbitan stearate 0.6 Isostearyl isostearate 5.0 Squalane 5.0 Mineral oil 35.0 Dimethicon 0.5 Hydroxyethyl cellulose 0.12 Glycerine 6.0 Tri-ethanolamine 0.7 Antiseptic, fragrant, colorant Small amount DW To be total Total 100
- One example of essence containing senkyunolide A of the present invention is formulated as below Table VIII: TABLE VIII Ingredients Amount (wt %) Senkyunolide A 1.5 Glycerine 10.0 Betaine 5.0 PEG 1500 2.0 Alantoine 0.1 DL-pantenol 0.3 EDTA-2Na 0.02 Benzophenon-9 0.04 Hydroxyethyl cellulose 0.1 Sodium hyaluronate 8.0 Carboxyvinyl polymer 0.2 Triethanolamine 0.18 Octyldodecanol 0.3 Octyldodeces-16 0.4 Ethanol 6.0 Antiseptic, fragrant, colorant Small amount DW To be total Total 100
- One example of facial pack containing senkyunolide A of the present invention is formulated as below Table IX: TABLE IX Ingredients Amount (wt %) Senkyunolide A 1.0 Polyvinyl alcohol 15.0 Cellulose gum 0.15 Glycerine 3.0 PEG 1500 2.0 Cyclodextrin 0.15 DL-pantenol 0.4 Alantoine 0.1 Monoammonium glycyrrhizinate 0.3 Nicotineamide 0.5 Ethanol 6.0 PEG 40 hydrogenated castor oil 0.3 Antiseptic, fragrant, colorant Small amount DW To be total Total 100
- the skin-whitening efficacy of the cosmetic compositions of the present invention was evaluated by practical use.
- the nutrient cream, containing 1.5% senkyunolide A, described in the Formulation IV was employed and senkyunolide A was substituted with the same amount of DW for control in this trial.
- the Formulation IV according to the present invention shows significantly enhanced whitening effect compared to its control formulation. Furthermore, there was no skin trouble in any testee.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to cosmetic compositions and more particularly to skin-whitening cosmetic compositions comprising senkyunolide A as an active ingredient. The present invention discloses the novel inhibitory function of senkyunolide A isolated from Cnidium officinale and Ligusticum chuanxiong on the melanocyte-stimulating hormone (MSH), and provides MSH-inhibitory compositions and skin-whitening cosmetic compositions comprising the senkyunolide A. The compositions of the present invention show significantly enhanced skin-whitening effect owing to its efficient inhibition of MSH even in lower concentration.
Description
- 1. Field of the Invention
- The present invention relates to a cosmetic composition and more particularly, to a cosmetic composition for skin whitening comprising senkyunolide A as an active ingredient and its applications.
- 2. Description of the Related Art
- Colors of human skin, hair and iris are ascribed to melanin, keratin and hemoglobin. The melanin has been considered as a pivotal factor for skin color and the color of skin is determined depending on the amount, disposition and distribution of melanin.
- The major factor of skin-darkening is over-expression of melanin. UV-irradiated epidermal keratinocytes secrete melanin-inducing factors resulting in synthesis of melanin from activated dermal melanocytes and the secreted melanin on epidermis pigments the skin.
- Detail mechanism of melanin synthesis has been investigated. In an activated melanocyte, tyrosinase converts tyrosine into dopaquinone and its oxidized derivative, dopachrome, is consecutively oxidized into 5,6-dihydroxyindole (DHI) and 5,6-dihydroxyindole-2-carboxylic acid (DHICA). The final copolymerization of the DHI and DHICA forms melanin.
- Currently, most inhibitors of melanin synthesis target the tyrosinase. Well-known tyrosinase inhibitors are kojic acid, albutin, hydroquinone, vitamin C and extracts of various natural materials.
- Recent years saw dramatic investigations both in terms of interrelation of keratinocyte and melanocyte, and cytokines secreted by keratinocytes. Among them, the roles of endothelin, prostaglandin, nitric oxide and melanocyte-stimulating hormone (MSH) in activation of melanocytes leading to melanogenesis have been reported several times.
- Therefore, the present inventors have been endeavored to alleviate the melanin-inducing stimuli such as UV irradiation and to inhibit the UV-derived physiological activity and synthesis of melanin-inducing factors. In particular, the present inventors gave a due investigation on candidate substances enabling to inhibit melanin synthesis induced by melanocyte-stimulating hormone (MSH).
- α-melanocyte stimulating hormone (CL MSH) expressed by UV irradiation or pregnancy binds to its receptor on melanocyte leading to increase of melanin via activation of melanocyte, tyrosinase and melanocyte dendrite. Consequently, it is highly probable to gain skin-whitening effect and alleviation of pigmentation by inhibiting a MSH. For that reason, the need of inhibitors for a MSH has been highly rising in the art.
- Having made intensive investigations on inhibition of melanocyte stimulating hormone (MSH) to provide inhibition of melanin synthesis and ultimately to achieve skin-whitening effect, the present inventors have identified the novel MSH-inhibitory function of senkyunolide A, a kind of phthalide extracted from Cnidium officinale and Ligusticum chuanxiong and observed an improved skin-whitening effect of cosmetic compositions comprising the senkyunolide A.
- Accordingly, it is an object of this invention to provide an inhibitory composition against MSH induced melanogenesis.
- It is another object of this invention to provide a cosmetic composition showing skin-whitening effect.
- Other objects and advantages of the present invention will become apparent from the detailed description to follow taken in conjugation with the appended claims and drawings.
- In one aspect of this invention, there is provided a cosmetic composition for skin whitening comprising: (a) a senkyunolide A as an active ingredient; and (b) a cosmetically acceptable carrier.
- In another aspect of this invention, there is provided a composition for inhibiting melanocyte-stimulating hormone (hereinafter, referred to as “MSH”) comprising senkyunolide A as an active ingredient.
- In an effort to follow the above need in the art, the present inventors had strived to develop inhibitors of MSH and finally found not only the extract of Cnidium officinale and Ligusticum chuanxiong with inhibitory activity to MSH but also the enhanced skin-whitening effect of cosmetic compositions comprising such extract, which is disclosed in Korean Patent Application NO.2002-25213, the teaching of which is incorporated herein by reference in its entity.
- As a proceeding investigation, the present inventors have endeavored to isolate an active ingredient from the extract of Cnidium officinale and Ligusticum chuanxiong and identified the MSH-inhibitory effect of senkyunolide A among various substances. This activity of senkyunolide A is conspicuous owing to its unprecedented discovery of the novel function.
- Senkyunolide A (3-butyl-6,7-dihydrophthalide), a naturally occurring phthalide, is represented by the following formula I:
- According to a preferred embodiment of the invention, the senkyunolide A used has been isolated from Cnidium officinale or Ligusticum chuanxiong, which are perennial herbs of Umbelliferae.
- Various phthalides are contained in the herbs. In particular, Cnidium officinale comprises ligustilide, butylidenephthalide, sekyunolide A and sekyunonlide H (Kobayashi S. et al., Antiproliferative effects of the traditional Chinese medicine shimotsu-to, its component Cnidium rhizome and derived compounds on primary cultures of mouse aorta smooth muscle cells. Jpn J Pharmacol. 1992. 60(4): 397-401) and Ligusticum chuanxiong comprises 3-butylphthaldie, 3-butylidenephthalide, 3-butylidene-4-hydroxyphthalide, neocnidilide, Z-ligustilide, E-ligustilide, senkyunolide A, senkyunolide F, senkyunolide H and senkyunolide I (Li H X. et al., Separation and identification of the phthalic anhydride derivatives of Liqusticum chuanxiong Hort by GC-MS, TLC, HPLC-DAD and HPLC-MS. 2002. J Chromatogr Sci. 40(3): 156-61).
- Among them, the senkyunolide A of the invention showed a novel MSH-inhibitory activity and more enhanced skin-whitening effect than conventional whitening agents showing inhibition of tyrosinase activity.
- Furthermore, the purified senkyunolide A according to the present invention is a potential candidate for skin-whitening agent since its IC 50 is much lower than extract of Cnidium officinale or Ligusticum chuanxiong.
- According to the present invention, although various organs and tissues such as roots, foliage, flowers, stems, fruitage and seeds from Cnidium officinale or Ligusticum chuanxiong can be employed, the most preferred source is roots.
- In a preferred embodiment, senkyunolide A of the present invention is isolated from the extract of Cnidium officinale or Ligusticum chuanxiong. The extract of Cnidium officinale or Ligusticum chuanxiong may be acquired using various extraction solvents, e.g. (a) water, (b) anhydrous or hydrous lower alcohol containing 1-4 carbon atoms (methanol, ethanol, propanol, butanol, etc.), (c) mixture of the lower alcohol and water, (d) acetone, (e) ethyl acetate, (f) chloroform, (g) 1,3-butyleneglycol, (h) butyl acetate. More preferable extraction solvent for this invention is the hydrous lower alcohol, and the most preferable solvent is ethanol. Furthermore, it is apparent to one skilled in the art that other conventional solvents may be employed for substantially similar isolating efficiency.
- Senkyunolide A according to the present invention can be isolated and purified from Cnidium officinale or Ligusticum chuanxiong using the known methods in the art. For instance, the isolation and purification may employ gas chromatography (GC), head space gas chromatography (HSGC), liquid chromatography (LC), high performance liquid chromatography (HPLC) and thin layer chromatography (TLC).
- Moreover, the present invention may employ senkyunolide A prepared by not only isolating from Cnidium officinale or Ligusticum chuanxiong extract but also synthesizing chemically.
- According to the preferred embodiment of the present invention, the effective amount of senkyunolide A in cosmetic composition is 0.00001-20 wt %, and more preferably 0.00001-10 wt % based on the total weight of the cosmetic composition.
- If the amount of senkyunolide A is lower than 0.00001 wt %, the aimed skin-whitening effect may be negligible; in the case of exceeding 20 wt %, some adverse effects such as skin irritation and instability in formulation is very likely to occur.
- Furthermore, the cosmetic compositions of the present invention may contain auxiliaries as well as carrier in addition to senkyunolide A. The non-limiting examples of auxiliaries include preservatives, antioxidants, stabilizers, solubilizers, vitamins, colorants, odor improvers or mixtures of these ingredients.
- The cosmetic compositions of this invention may be formulated in a wide variety of form, for non-limited example, including a solution, a suspension, an emulsion, a paste, an ointment, a gel, a cream, a lotion, a powder, a soap, a surfactant-containing cleanser, an oil, a powder foundation, an emulsion foundation, a wax foundation and a spray. In detail, the cosmetic composition of the present invention can be provided in a form of skin softener (skin lotion), astringent lotion, nutrient emulsion (milk lotion), nutrient cream, message cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, facial pack, spray or powder.
- The cosmetically acceptable carrier contained in the present cosmetic composition, may be varied depending on the type of the formulation. For example, the formulation of ointment, pastes, creams or gels may comprise animal and vegetable fats, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silica, talc, zinc oxide or mixtures of these ingredients.
- In the formulation of powder or spray, it may comprise lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder and mixtures of these ingredients. Spray may additionally comprise the customary propellants, for example, chlorofluorohydrocarbons, propane/butane or dimethyl ether.
- The formulation of solution and emulsion may comprise solvent, solubilizer and emulsifier, for example water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyleneglycol, oils, in particular cottonseed oil, groundnut oil, maize germ oil, olive oil, castor oil and sesame seed oil, glycerol fatty esters, polyethylene glycol and fatty acid esters of sorbitan or mixtures of these ingredients.
- The formulation of suspension may comprise liquid diluents, for example water, ethanol or propylene glycol, suspending agents, for example ethoxylated isosteary alcohols, polyoxyethylene sorbitol esters and poly oxyethylene sorbitan esters, micocrystalline cellulose, aluminum metahydroxide, bentonite, agar and tragacanth or mixtures of these ingredients.
- The formulation of cleansing compositions with surfactant may comprise aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosucinnate monoester, isothinate, imidazolium derivatives, methyltaurate, sarcocinate, fatty acid amide ether sulfate, alkyl amido betain, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanoline derivatives, ethoxylated glycerol fatty acid ester or mixtures of these ingredients.
- The following specific examples are intended to be illustrative of the invention and should not be construed as limiting the scope of the invention as defined by appended claims.
- Materials
- The roots from Cnidium officinale or Ligusticum chuanxiong employed for extraction and purification of senkyunolide A were purchased from Kyung-dong Oriental Medicine Market in Seoul, Korea.
- 3 kg of the dried root powders (from Cnidium officinale or Ligusticum chuanxiong) were immersed in 18 L of ethanol for 3-5 days, filtered through Whattman No. 5 paper filter and dried in a vacuous rotary evaporator equipped with cooling condenser. The dried powder obtained thus was fractionated in a mixture of ethylacetate and distilled water and the ethylacetate layer was evaporated under vacuum. The dried substance was loaded on an open silica column (normal hexane:ethylacetate=3:1) and the fraction with Rf=0.5 was collected and evaporated, thus yielding 30.1 g of product. The value of Rf=0.5 was pre-determined via prep-TLC with the control of senkyunolide A commercially available. Among the product, 3.1 g of senkyunolide A was finally purified through prep-LC, distillation under vacuum and removal of residual solvent using vacuum pump, consecutively:
- Exact Mass: 192.12; ms (m/z (%)) 192 (17.19), 163 (1.91), 135 (3.57), 107 (100); 1HNMR 6.21 (dt), 5.91 (dt), 4.93 (dd) 2.47-1.39 (m), 0.9 (t); IR 2932, 2872, 1747, 1241 cm−1; UV (207, 278 nm).
- The inhibitory effect of the senkyunolide A purified through the Example I on activity of MSH was tested as follows:
- Melanocytes (mouse B-16 melanoma strain; ATCC CRL 6323) were purchased from ATCC (USA). The melanocytes were maintained in T-flask supplemented with DMEM containing 4.5 g/L glucose, 10% FBS (fetal bovine serum) and 1% penicillin-streptomycin in a humidified incubator supplied with 5% CO 2 at 3° C. After 24 h incubation, cells were detached by trypsinization and 5×104 cells were plated on each 100 mm plate supplemented with fresh medium. After additional incubation for 24 h, cells were pretreated with the senkyunolide A in a dose dependent manner (0, 5, 10, 20 and 50 μg/ml) and activated with 100 μM of α-melanocyte stimulating hormone (α MSH, Sigma, USA). The amount of melanin was measured after incubation for 5 days. Melanin samples were stirred in 5% trichloroacetate (TCA), centrifuged and rinsed with PBS. Precipitated melanin was resolved in 1N NaOH and absorbance was measured at 475 nm. Inhibitory potential of melanin synthesis was calculated based on standard curve acquired by synthetic melanin (Sigma, USA). The results are summarized in the following Table I:
TABLE I Conc. of Senkyunolide A Synthesis (μg/ml) of Melanin (%) 0* 100.0 0** 175.8 5** 160.6 10** 121.3 20** 105.5 50** 98.7 - As shown in Table I, senkyunolide A according to the present invention was found to decrease melanin synthesis of melanocytes induced by MSH in a dose dependent manner and 50 μg/ml of senkyunolide A inhibited the melanin synthesis to the level below the amount of MSH-uninduced melanocytes (100%). These data show the pivotal role of the senkyunolide A of the present invention in the inhibition of MSH activity and consequent melanin decrease.
- Melanocyts were plated in the same manner as Experiment Example I, pretreated with senkyunolide A in a dose dependent manner (0, 5, 10, 20 and 50 μg/ml) and activated with 100 μl of α-melanocyte stimulating hormone. Melanocytes were harvested after 3 days incubation. The harvested cells were rinsed twice in PBS and ultrasonicated in 0.1% Triton X-100 for 30 seconds. Cell debris was separated from supernatant by high speed centrifugation (12,000 rpm, 30 mins, 4° C.). Proteins in supernatant were separated by electrophoresis, the gels were reacted in 0.2% dopa solution for 8 h and the level of tyrosinase was measured. The results are summarized in the following Table II:
TABLE II Conc. Of Senkyunolide A Tyrosinae (μg/ml) band intensity 0* 100.0 0** 205.0 5** 185.0 10** 153.0 20** 132.0 50** 101.0 - As shown in Table II, senkyunolide A of the present invention was found to decrease the tyrosinase expression in melanocytes in a dose dependent manner and 50 μg/ml senkyunolide A caused the similar band intensity to tyrosinase of MSH-uninduced melanocytes. These data show the enhanced inhibitory effect of the senkyunolide A on melanin synthesis.
- From the results of Experimental Examples I and II, it will be appreciated that the inhibitory action of senkyunolide A in signal transduction cascade for melanin synthesis occurs further upstream, i.e., at MSH than conventional whitening agents of which target is tyrosinase. Therefore, senkyunolide A of this invention is very likely to exhibit improved whitening effect and to show the similar effect to conventional whitening agents even in lower level.
- The formulations of the present invention can be provided in a form of skin softener (skin lotion), astringent lotion, nutrient emulsion (milk lotion), nutrient cream, message cream, essence, facial pack without limiting the applicable formulations therein.
- Formulation I: Skin Lotion (Skin Softener)
- One example of skin lotion containing senkyunolide A according to the present invention is formulated as below:
TABLE III Ingredients Amount (wt %) Senkyunolide A 1.0 Glycerine 5.0 1,3-butylglycol 3.0 PEG 150 1.0 Alantoine 0.1 DL-pantenol 0.3 EDTA-2Na 0.02 Benzophenon-9 0.04 Sodium hyaluronate 5.0 Ethanol 10.0 Octyldodeces-16 0.2 Polysorbate 20 0.2 Antiseptic, fragrant, colorant Small amount DW To be total Total 100 - Formulation II: Astringent Lotion
- One example of the astringent lotion containing senkyunolide A of the present invention is formulated as below Table IV:
TABLE IV Ingredients Amount (wt %) Senkyunolide A 1.0 Glycerine 2.0 1,3-butylglycol 2.0 Alantoine 0.2 DL-pantenol 0.2 EDTA-2Na 0.02 Benzophenon-9 0.04 Sodium hyaluronate 3.0 Ethanol 15.0 Polysorbate 20 0.3 Witchhazel extract 2.0 Citric acid Small amount Antiseptic, fragrant, colorant Small amount DW To be total Total 100 - Formulation III: Nutrient Emulsion (Milk Lotion)
- One example of the nutrient emulsion containing senkyunolide A of the present invention is formulated as below Table V:
TABLE V Ingredients Amount (wt %) Senkyunolide A 1.5 Glyceryl stearate SE 1.5 Stearyl alcohol 1.5 Lanoline 1.5 Polysorbate 60 1.3 Sorbitan stearate 0.5 Hydrogenated vegetable oil 1.0 Mineral oil 5.0 Squalane 3.0 Trioctanoine 2.0 Dimethicon 0.8 Tocopherol acetate 0.5 Carboxyvinyl polymer 0.12 Glycerine 5.0 1,3-butylglycol 3.0 Sodium hyaluronate 5.0 Tri-ethanolamine 0.12 Antiseptic, fragrant, colorant Small amount DW To be total Total 100 - Formulation IV: Nutrient Cream
- One example of nutrient cream containing senkyunolide A of the present invention is formulated as below Table VI:
TABLE VI Ingredients Amount (wt %) Senkyunolide A 5.0 Lypophilic glycerol monostearate 2.0 Cetearyl alcohol 2.2 Stearic acid 1.5 Wax 1.0 Polysorbate 60 1.5 Sorbitan stearate 0.6 Hydrogenated vegetable oil 1.0 Squalane 3.0 Mineral oil 5.0 Trioctanoine 5.0 Dimethicon 1.0 Sodium magnesium silicate 0.1 Glycerine 5.0 Betaine 3.0 Tri-ethanolamine 1.0 Sodium hyaluronate 4.0 Antiseptic, fragrant, colorant Small amount DW To be total Total 100 - Formulation V: Message Cream
- One example of message cream containing senkyunolide A of the present invention is formulated as below Table VII:
TABEL VII Ingredients Amount (wt %) Senkyunolide A 1.0 Lypophilic glycerol monostearate 1.5 Stearyl alcohol 1.5 Stearic acid 1.0 Polysorbate 60 1.5 Sorbitan stearate 0.6 Isostearyl isostearate 5.0 Squalane 5.0 Mineral oil 35.0 Dimethicon 0.5 Hydroxyethyl cellulose 0.12 Glycerine 6.0 Tri-ethanolamine 0.7 Antiseptic, fragrant, colorant Small amount DW To be total Total 100 - Formulation VI: Essence
- One example of essence containing senkyunolide A of the present invention is formulated as below Table VIII:
TABLE VIII Ingredients Amount (wt %) Senkyunolide A 1.5 Glycerine 10.0 Betaine 5.0 PEG 1500 2.0 Alantoine 0.1 DL-pantenol 0.3 EDTA-2Na 0.02 Benzophenon-9 0.04 Hydroxyethyl cellulose 0.1 Sodium hyaluronate 8.0 Carboxyvinyl polymer 0.2 Triethanolamine 0.18 Octyldodecanol 0.3 Octyldodeces-16 0.4 Ethanol 6.0 Antiseptic, fragrant, colorant Small amount DW To be total Total 100 - Formulation VII: Facial Pack
- One example of facial pack containing senkyunolide A of the present invention is formulated as below Table IX:
TABLE IX Ingredients Amount (wt %) Senkyunolide A 1.0 Polyvinyl alcohol 15.0 Cellulose gum 0.15 Glycerine 3.0 PEG 1500 2.0 Cyclodextrin 0.15 DL-pantenol 0.4 Alantoine 0.1 Monoammonium glycyrrhizinate 0.3 Nicotineamide 0.5 Ethanol 6.0 PEG 40 hydrogenated castor oil 0.3 Antiseptic, fragrant, colorant Small amount DW To be total Total 100 - Experiment 3: Skin-Whitening Efficacy of the Cosmetic Compositions of the Present Invention
- The skin-whitening efficacy of the cosmetic compositions of the present invention was evaluated by practical use. The nutrient cream, containing 1.5% senkyunolide A, described in the Formulation IV was employed and senkyunolide A was substituted with the same amount of DW for control in this trial.
- At first, 20 women aged from 30 to 40 were caused skin-pigmentation by UV irradiation. Their randomized 2 groups were applied with the nutrient cream of the Formulation IV or its control cream. The application in upper arms lasted for 2 months with diurnal twice applications in every morning and night. Whitening efficacy was evaluated by observation compared to control groups. The results are summarized in the following Table X:
TABLE X Moderately Effective effective Ineffective Efficacy (%) Formulation IV 41 6 3 94.0 Control 5 12 33 34.0 - As shown in Table X, the Formulation IV according to the present invention shows significantly enhanced whitening effect compared to its control formulation. Furthermore, there was no skin trouble in any testee.
- Having described preferred embodiments of the present invention, it is to be understood that variants and modifications thereof falling within the spirit of the invention may become apparent to those skilled in this art, and the scope of this invention is to be determined by appended claims and their equivalents.
Claims (6)
1. A cosmetic composition for skin whitening comprising:
(a) a senkyunolide A as an active ingredient; and
(b) a cosmetically acceptable carrier.
2. A composition for inhibiting melanocyte-stimulating hormone (MSH) comprising senkyunolide A as an active ingredient.
3. The composition according to claim 1 or 2, wherein the senkyunolide A is purified from Cnidium officinale and Ligusticum chuanxiong.
4. The composition according to claim 1 or 2, wherein the senkyunolide A is chemically synthesized.
5. The cosmetic composition according to claim 1 , wherein the senkyunolide A is present in an amount of 0.00001-20 wt % based on the total weight of the composition.
6. The cosmetic composition according to claim 1 , wherein the composition is in the form of one selected from a solution, a suspension, an emulsion, a paste, an ointment, a gel, a cream, a lotion, a powder, a soap, a surfactant-containing cleanser, an oil, a powder foundation, an emulsion foundation, a wax foundation and a spray
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/389,284 US7846967B2 (en) | 2002-10-29 | 2006-03-27 | Cosmetic composition for skin whitening comprising senkyunolide A as active ingredient |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR2002-66050 | 2002-10-29 | ||
| KR10-2002-0066050A KR100504408B1 (en) | 2002-10-29 | 2002-10-29 | Cosmetic Composition for Skin-Whitening Comprising Senkyunolide A as Active Ingredient |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/389,284 Division US7846967B2 (en) | 2002-10-29 | 2006-03-27 | Cosmetic composition for skin whitening comprising senkyunolide A as active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20040081631A1 true US20040081631A1 (en) | 2004-04-29 |
Family
ID=36696977
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/353,010 Abandoned US20040081631A1 (en) | 2002-10-29 | 2003-01-29 | Cosmetic composition for skin whitening comprising senkyunolide a as active ingredient |
| US11/389,284 Active 2026-08-10 US7846967B2 (en) | 2002-10-29 | 2006-03-27 | Cosmetic composition for skin whitening comprising senkyunolide A as active ingredient |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/389,284 Active 2026-08-10 US7846967B2 (en) | 2002-10-29 | 2006-03-27 | Cosmetic composition for skin whitening comprising senkyunolide A as active ingredient |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20040081631A1 (en) |
| JP (1) | JP3889366B2 (en) |
| KR (1) | KR100504408B1 (en) |
| CN (1) | CN1247182C (en) |
| FR (1) | FR2846239B1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040166069A1 (en) * | 2003-02-21 | 2004-08-26 | Gupta Shyam K. | Boosting Tyrosinase Inhibiting Activity of Skin Whitening and Sunscreen Compositions |
| US20070042057A1 (en) * | 2003-09-23 | 2007-02-22 | Dsm Ip Assets B.V. | Compositions for the treatment and prevention of diabetes mellitus |
| US20070082947A1 (en) * | 2003-05-14 | 2007-04-12 | D Orazio Daniel | Use of phthalide derivatives for the treatment and prevention of diabetes mellitus |
| CN113413379A (en) * | 2021-06-28 | 2021-09-21 | 中国人民解放军海军军医大学第一附属医院 | Application of senkyunolide I in medicine for treating sepsis and lung injury |
| CN116236408A (en) * | 2023-03-29 | 2023-06-09 | 云南贝泰妮生物科技集团股份有限公司 | A whitening composition derived from three active ingredients of traditional Chinese medicine and its application |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100678864B1 (en) * | 2005-08-30 | 2007-02-05 | 주식회사 코리아나화장품 | Cosmetic composition for skin whitening containing cheongung extract and carnitine as active ingredients |
| KR100713556B1 (en) * | 2005-12-26 | 2007-05-04 | 주식회사 코리아나화장품 | Cosmetic composition for skin whitening containing cheongung extract and hexanoyl tripeptide as an active ingredient |
| KR100744947B1 (en) * | 2005-12-27 | 2007-08-02 | 주식회사 코리아나화장품 | Cosmetic composition for skin whitening containing cheongung extract and protease as active ingredients |
| KR100905035B1 (en) * | 2007-06-01 | 2009-06-30 | 중앙대학교 산학협력단 | Cosmetic composition for skin whitening containing phenolic compound isolated from wood vinegar extract as an active ingredient |
| CN104447648B (en) * | 2014-10-27 | 2016-05-04 | 重庆方通动物药业有限公司 | A kind of supercritical CO2Fluid is prepared the method for Senkyunolide A from Ligusticum chuanxiong Hort |
| FR3034314B1 (en) | 2015-03-30 | 2019-10-04 | Sederma | TOPICAL COSMETIC TREATMENT OF SKIN AND SCALP LEATHER AND CORRESPONDING ACTIVE INGREDIENT BASED ON AN EXTRACT FROM APIUM GRAVEOLENS |
| KR101772934B1 (en) | 2015-07-22 | 2017-08-31 | 주식회사 나투젠 | Composition for skin whitening comprising peptide coupled kojic acid derivatives |
| FR3056401B1 (en) * | 2016-09-27 | 2020-01-10 | Sederma | TOPICAL SLIMMING COSMETIC TREATMENT |
| CN106821803B (en) * | 2017-02-09 | 2019-11-29 | 四川新绿色药业科技发展有限公司 | A kind of Rhizoma Chuanxiong essential oil composition and its preparation method and application |
| CN110412199A (en) * | 2019-07-18 | 2019-11-05 | 四川绿色本草科技发展有限公司 | A kind of quality determining method of Rhizoma Chuanxiong toothpaste |
| JP2021088522A (en) * | 2019-12-03 | 2021-06-10 | 株式会社コーセー | V-atpase activity promoter |
| CN111388367B (en) * | 2020-03-25 | 2021-09-24 | 江南大学 | A kind of composition and preparation method of multi-target inhibiting melanin and its application in cosmetics |
| CN112461977A (en) * | 2020-12-14 | 2021-03-09 | 中国科学院兰州化学物理研究所 | Phthalide compound standard substance and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326006B1 (en) * | 1988-09-02 | 2001-12-04 | Kao Corporation | Bathing preparation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5279032A (en) * | 1975-12-24 | 1977-07-02 | Sunstar Inc | Crude drug compound |
| JPS5388333A (en) * | 1977-01-13 | 1978-08-03 | Sunstar Inc | Cosmetics |
| JPS5692208A (en) * | 1979-12-27 | 1981-07-25 | Sunstar Inc | External preparation for skin whitening |
| JPH05186324A (en) * | 1991-12-29 | 1993-07-27 | Sunstar Inc | Beautifying cosmetic |
| JP3407935B2 (en) * | 1993-06-30 | 2003-05-19 | 三省製薬株式会社 | External preparation for skin |
| JPH1025236A (en) * | 1996-07-10 | 1998-01-27 | Pola Chem Ind Inc | Agent for improving and reinforcing nonuniformity of skin and cosmetic containing the same |
| JPH10265321A (en) * | 1997-03-19 | 1998-10-06 | Shiseido Co Ltd | Skin preparation for external use |
| JP2002179516A (en) * | 2000-12-13 | 2002-06-26 | Pola Chem Ind Inc | Skin-whitening composition |
| KR20030087236A (en) * | 2002-05-08 | 2003-11-14 | 주식회사 코리아나화장품 | Cosmetic Composition for Skin-Whitening Comprising Extract of Cnidium officinale |
-
2002
- 2002-10-29 KR KR10-2002-0066050A patent/KR100504408B1/en not_active Expired - Lifetime
-
2003
- 2003-01-15 FR FR0300394A patent/FR2846239B1/en not_active Expired - Lifetime
- 2003-01-28 CN CNB031034683A patent/CN1247182C/en not_active Expired - Lifetime
- 2003-01-29 US US10/353,010 patent/US20040081631A1/en not_active Abandoned
- 2003-01-31 JP JP2003023372A patent/JP3889366B2/en not_active Expired - Fee Related
-
2006
- 2006-03-27 US US11/389,284 patent/US7846967B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326006B1 (en) * | 1988-09-02 | 2001-12-04 | Kao Corporation | Bathing preparation |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040166069A1 (en) * | 2003-02-21 | 2004-08-26 | Gupta Shyam K. | Boosting Tyrosinase Inhibiting Activity of Skin Whitening and Sunscreen Compositions |
| US20070082947A1 (en) * | 2003-05-14 | 2007-04-12 | D Orazio Daniel | Use of phthalide derivatives for the treatment and prevention of diabetes mellitus |
| US20090192218A1 (en) * | 2003-05-14 | 2009-07-30 | D Orazio Daniel | Use of phthalide derivatives for the treatment and prevention of diabetes mellitus |
| US8242168B2 (en) | 2003-05-14 | 2012-08-14 | Dsm Ip Assets B.V. | Use of phthalide derivatives for the treatment of type 2 diabetes mellitus |
| US20070042057A1 (en) * | 2003-09-23 | 2007-02-22 | Dsm Ip Assets B.V. | Compositions for the treatment and prevention of diabetes mellitus |
| US7691420B2 (en) | 2003-09-23 | 2010-04-06 | Dsm Ip Assets B.V. | Compositions for the treatment and prevention of diabetes mellitus |
| CN113413379A (en) * | 2021-06-28 | 2021-09-21 | 中国人民解放军海军军医大学第一附属医院 | Application of senkyunolide I in medicine for treating sepsis and lung injury |
| CN116236408A (en) * | 2023-03-29 | 2023-06-09 | 云南贝泰妮生物科技集团股份有限公司 | A whitening composition derived from three active ingredients of traditional Chinese medicine and its application |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040037521A (en) | 2004-05-07 |
| US20060165619A1 (en) | 2006-07-27 |
| FR2846239B1 (en) | 2006-08-04 |
| US7846967B2 (en) | 2010-12-07 |
| CN1493270A (en) | 2004-05-05 |
| CN1247182C (en) | 2006-03-29 |
| JP2004149505A (en) | 2004-05-27 |
| JP3889366B2 (en) | 2007-03-07 |
| FR2846239A1 (en) | 2004-04-30 |
| KR100504408B1 (en) | 2005-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7846967B2 (en) | Cosmetic composition for skin whitening comprising senkyunolide A as active ingredient | |
| CN101686929B (en) | A cosmetic composition for skin whitening comprising the extract of magnolia sieboldii as active ingredient | |
| KR102414390B1 (en) | A composition for antioxidating, whitening and improving wrinkle comprising flower extract | |
| KR102436291B1 (en) | Cosmetic Composition for Skin Whitening Containing Eleutheroside E As Active Ingredient | |
| JP5154835B2 (en) | Whitening cosmetics | |
| KR101050484B1 (en) | Skin whitening composition containing lactone compound as an active ingredient | |
| KR102044935B1 (en) | Whitening or moisturizing cosmetic composition comprising the extract of Cicer Arietinum | |
| KR102325393B1 (en) | Skin whitening cosmetic composition with bioconversion of Breea segeta extract | |
| KR102331903B1 (en) | Cosmetic Composition comprising Spergularia marina Extract | |
| KR101427027B1 (en) | A Skin External Composition Containing Callus Extract Derived from Chaenomeles Sinensis | |
| KR100678864B1 (en) | Cosmetic composition for skin whitening containing cheongung extract and carnitine as active ingredients | |
| KR100515125B1 (en) | Cosmetic Composition for Skin-Whitening Comprising Ramulus Mori Extracts and Niacinamide as Active Ingredients | |
| KR102268130B1 (en) | Cosmetic Composition comprising Polygonum vellardii All Extract | |
| KR102810314B1 (en) | A cosmetic composition for skin whitening comprising a mixed extract of Geranium kunthii and Zephyrnathes candida as an active ingredient, and a pharmaceutical composition for preventing or treating diseases of melanin hyperpigmentation | |
| KR102308715B1 (en) | Cosmetic Composition comprising Atriplex gmelini Extract | |
| KR102491296B1 (en) | Skin whitening cosmetic composition using pear peel | |
| KR100678865B1 (en) | Cosmetic composition for skin whitening containing upper limb extract and carnitine as active ingredients | |
| KR102365223B1 (en) | Low irritating cosmetic composition for skin whitening comprising albutin, Polygonum tinctorium leaf and Brassica napus whole plant | |
| KR102365222B1 (en) | Low irritating cosmetic composition for skin whitening comprising albutin, Polygonum tinctorium leaf and Betula platyphylla japonica bark extract | |
| US20120213875A1 (en) | Cosmetic composition for skin whitening comprising the extract of magnolia sieboldii as active ingredient | |
| KR20040059006A (en) | Skin Whitening Cosmetic containing a herb extract with inhibitory activity of melanin formation | |
| KR20250095782A (en) | Novel compounds having skin whitening activity and the process for the preparation thereof | |
| KR20250113023A (en) | Method for producing whitening functional peptide derived from black bean fermentation filtrate and cosmetic composition using the same | |
| KR20070006339A (en) | Skin Whitening Composition | |
| KR20190129556A (en) | Composition for skin whitening comprising Aster koraiensis extract or fraction thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: COREANA COSMETICS CO., LTD., KOREA, REPUBLIC OF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEE, KANG-TAE;LEE, JUNG-NO;JEONG, JEE-HEAN;AND OTHERS;REEL/FRAME:013720/0727 Effective date: 20030116 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |